NewAmsterdam Pharma Corporation

We're pleased to announce today is our Nasdaq listing day! We've begun trading under NAMS as we continue our work to bring obicetrapib, a transformative, clinically validated, oral therapy, to patients with cardiometabolic diseases. https://bit.ly/3VjBY3c #NasdaqListed

Our team spent the weekend at the 56th Annual Scientific Meeting of the Japan Atherosclerosis Society, including hosting a lunch seminar led by Prof. John Kastelein and Prof. Stephen Nicholls exploring CETP as a therapeutic target for the clinical management of LDL-C.

We’re excited to announce patient enrollment is complete in our pivotal Phase 3 TANDEM clinical trial. https://bit.ly/4czF7F8   The study evaluates the fixed-dose combination of our lead investigational candidate, obicetrapib, plus ezetimibe in adults with heterozygous familial hypercholesterolemia, ASCVD, or multiple ASCVD risk factors whose LDL-C is not adequately controlled with maximally tolerated lipid-modifying therapies.

Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs. #biotech #pharma

A recent JAMA Cardiology study found that higher Lp(a) was associated with increased cardiovascular risk regardless of hs-CRP levels. We are investigating the potential effects of CETP inhibition on Lp(a). https://bit.ly/3Ljp8ix

A survey of patients in the GOULD Registry found that <1/3 identified that the primary reason they were taking lipid-lowering medication was to lower the risk of a heart attack or stroke. Most physicians surveyed (66%) agreed that a lack of understanding was the primary driver of nonadherence to therapies. https://bit.ly/3RH0fRa

Now live on Healio: "CETP Inhibitors: On the Horizon for Cardiovascular Risk Reduction." This activity is supported by an educational grant from NewAmsterdam Pharma Corporation and provided by Vindico Medical Education. Click here to earn #CME: https://bit.ly/4exgoT5

Research from The Family Heart Foundation shows only 2.2% of high-risk Americans ever receive more than one lipid-lowering medication. Combination therapy could potentially help more people reach their LDL-C goals, reducing the risk of cardiovascular disease. 

Our team connected with researchers and clinicians at the Heart in Diabetes conference in Philadelphia this past weekend, sharing six abstracts and taking home an award for our “significant contribution to the science of dyslipidemia in the prevention and management of atherosclerosis in diabetes, cardiovascular and metabolic diseases.” #HID24 Pictured: Naina Chhokar, Kelley Gorbe, PharmD, BCMAS, & Bill Lester, Ph.D.

The U.S. Patent and Trademark Office has issued a new composition of matter patent for obicetrapib, our investigational CETP inhibitor, extending intellectual property protection for an additional nine years until July 2043. https://bit.ly/4cgXVZa